Endocrine Abstracts

We report the case of a 36 years old female, with personal history of breast cancer, treated with neoadjuvant chemotherapy, breast sectorectomy and then chemotherapy and radiation therapy 2 years ago. She was continuously monitored by her oncologist, disease free for over a year, with recent CT scan that showed no particular lessions suggestive for secondary disease. Meanwhile, she got pregnant and delivered at term a healthy baby. She was admitted 3 months postpartum with int...

Introduction: Neuroendocrine tumors (NET) represent a heterogeneous group of tumors with different locations, whose management is based on the pathology, immunohistochemical, genetic and molecular profile.Materials and method: We followed 8 patients with NET between 2014 and 2022 registered at the “C.I. Parhon” National Institute of Endocrinology, Bucharest, who benefited from peptide receptor radionuclide therapy (PRRT). Among them, 75% were m...

Aggressive pituitary tumors (APT) causing Cushing’s Disease are very rare, difficult to treat. The majority of Crooke’s corticotropinomas are macroadenomas, exhibiting rapid growth, resistance to conventional treatments, a high recurrence rate. To date, there is no fully effective method of treatment for these tumors. Pituitary carcinomas (PC) are defined by distant metastasis. PC is exceedingly rare, comprising only 0.1–0.2% of all pituitary neoplasms but APT m...

IntroductionThyrotropinoma is a rare pituitary tumor ( <2% of pituitary adenomas) arising from PIT1-lineage cells, which expresses and secrete TSH. In most cases, the etiology is unknown but rare cases have been described to arise in context of MEN 1 syndrome. Diagnosis is often delayed by confusion with primary hyperthyroidism, which determine the tumor to be already large and invasive at the time of diagnosis. GH and prolactin cosecretion is an increas...

Introduction: Pituitary adenomas are the most common pituitary tumours, but in 18% of cases we can find other rare tumours like: Rathke’s cleft cyst, craniopharingyomas, chordomas, meningiomas, infiltrative or infectious disease. Meningeal melanocytoma is a benign neoplasm of central nervous system, commonly located in the base of the brain, cerebellopontine angle and the pineal body, difficult to differentiate from a nonfunctional p...

Introduction: Pituitary adenomas are the most common pituitary tumours, but in 18% of cases we can find other rare tumours like: Rathke’s cleft cyst, craniopharingyomas, chordomas, meningiomas, infiltrative or infectious disease. Meningeal melanocytoma is a benign neoplasm of central nervous system, commonly located in the base of the brain, cerebellopontine angle and the pineal body, difficult to differentiate from a nonfunctional p...

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder caused by germline mutations of MEN1 gene, without genotype–phenotype correlation. It is defined as the occurrence of two or more primary neuroendocrine tumors (parathyroid, enteropancreatic, pituitary), or the occurrence of one of the MEN1-associated tumors in family members of a patient with a clinical diagnosis of MEN1. Multiple parathyroid tumors with hyperparathyroidism are the most common m...

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor derived from the thyroid C cells producing calcitonin, ac-counts for 0.6% of all thyroid cancers. It occurs either sporadically or in a hereditary form (RET mutation). MTC can be cured only by complete resection of the thyroid tumor and any loco-regional metastases. Calcitonin (CT) measurement is crucial to the early diagnosis and the follow-up of MTC. If the evaluation of stimulated CT levels is required, a prov...

Giant prolactinoma it’s a very rare tumor that due to its massive extension into surrounding structures can present more often with neurological complications such as visual defects, cranial nerve paresis or even hydrocephalus, unlike the classic prolactinoma presentation with amenorrhea, infertility and galactorrhea. On CT/MRI exams it can present as aggressive skull base tumor and its immunohistochemistry (IHC) may have common features with neuroendocrine neoplasms....

Background: Suitable postoperative radiotherapy (RT) of nonfunctioning pituitary macroadenomas (NFMAs) is still controversial, subjected to rapid technical and medical progress.Patients and methods.: We studied 87 patients with NFMA to identify factors affecting tumor control such as the time of RT and tumor pathology. Partial pituitary surgery was performed either by transfrontal (30 patients) or transsphenoidal (57 patients) approach. An immunoperoxida...